Global Nucleic Acid-based Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our latest research, the global Nucleic Acid-based Drugs market size will reach USD million in 2030, growing at a CAGR of % over the analysis period.

The Nucleic Acid-based Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Market segmentation
Nucleic Acid-based Drugs market is split by Type and by Application. For the period 2024-2030, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    ASO
    mRNA
    siRNA
    miRNA
    saRNA
    Aptamer

Market segment by Application, can be divided into
    Genetic Disease
    Cancer
    Cardiovascular Diseases
    Other

Market segment by players, this report covers
    Ionis Pharmaceuticals
    Sarepta Therapeutics
    Nippon Shinyaku
    BioNTech
    Moderna Therapeutics
    CureVac
    Alnylam Pharmaceuticals
    Regulus Therapeutics
    Miragen Therapeutics
    Mina Therapeutics
    NeXstar Pharmaceuticals

Market segment by regions, regional analysis covers
    North America
    Europe
    Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)
    South America
    Middle East & Africa

The content of the study subjects, includes a total of 8 chapters:
Chapter 1, to describe Nucleic Acid-based Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Nucleic Acid-based Drugs, with recent developments and future plans
Chapter 3, the Nucleic Acid-based Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4, to break the market size data at the region level, with key companies in the key region and Nucleic Acid-based Drugs market forecast, by regions, with revenue, from 2024 to 2030.
Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2024 to 2030.
Chapter 7 and 8, to describe Nucleic Acid-based Drugs research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Nucleic Acid-based Drugs
    1.2 Classification of Nucleic Acid-based Drugs by Type
        1.2.1 Overview: Global Nucleic Acid-based Drugs Market Size by Type: 2024 Versus 2030
        1.2.2 Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2030
        1.2.3 ASO
        1.2.4 mRNA
        1.2.5 siRNA
        1.2.6 miRNA
        1.2.7 saRNA
        1.2.8 Aptamer
    1.3 Global Nucleic Acid-based Drugs Market by Application
        1.3.1 Overview: Global Nucleic Acid-based Drugs Market Size by Application: 2024 Versus 2030
        1.3.2 Genetic Disease
        1.3.3 Cancer
        1.3.4 Cardiovascular Diseases
        1.3.5 Other
    1.4 Global Nucleic Acid-based Drugs Market Size & Forecast
    1.5 Market Drivers, Restraints and Trends
        1.5.1 Nucleic Acid-based Drugs Market Drivers
        1.5.2 Nucleic Acid-based Drugs Market Restraints
        1.5.3 Nucleic Acid-based Drugs Trends Analysis

2 Company Profiles
    2.1 Ionis Pharmaceuticals
        2.1.1 Ionis Pharmaceuticals Details
        2.1.2 Ionis Pharmaceuticals Major Business
        2.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
        2.1.4 Ionis Pharmaceuticals Recent Developments and Future Plans
    2.2 Sarepta Therapeutics
        2.2.1 Sarepta Therapeutics Details
        2.2.2 Sarepta Therapeutics Major Business
        2.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions
        2.2.4 Sarepta Therapeutics Recent Developments and Future Plans
    2.3 Nippon Shinyaku
        2.3.1 Nippon Shinyaku Details
        2.3.2 Nippon Shinyaku Major Business
        2.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions
        2.3.4 Nippon Shinyaku Recent Developments and Future Plans
    2.4 BioNTech
        2.4.1 BioNTech Details
        2.4.2 BioNTech Major Business
        2.4.3 BioNTech Nucleic Acid-based Drugs Product and Solutions
        2.4.4 BioNTech Recent Developments and Future Plans
    2.5 Moderna Therapeutics
        2.5.1 Moderna Therapeutics Details
        2.5.2 Moderna Therapeutics Major Business
        2.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions
        2.5.4 Moderna Therapeutics Recent Developments and Future Plans
    2.6 CureVac
        2.6.1 CureVac Details
        2.6.2 CureVac Major Business
        2.6.3 CureVac Nucleic Acid-based Drugs Product and Solutions
        2.6.4 CureVac Recent Developments and Future Plans
    2.7 Alnylam Pharmaceuticals
        2.7.1 Alnylam Pharmaceuticals Details
        2.7.2 Alnylam Pharmaceuticals Major Business
        2.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
        2.7.4 Alnylam Pharmaceuticals Recent Developments and Future Plans
    2.8 Regulus Therapeutics
        2.8.1 Regulus Therapeutics Details
        2.8.2 Regulus Therapeutics Major Business
        2.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions
        2.8.4 Regulus Therapeutics Recent Developments and Future Plans
    2.9 Miragen Therapeutics
        2.9.1 Miragen Therapeutics Details
        2.9.2 Miragen Therapeutics Major Business
        2.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions
        2.9.4 Miragen Therapeutics Recent Developments and Future Plans
    2.10 Mina Therapeutics
        2.10.1 Mina Therapeutics Details
        2.10.2 Mina Therapeutics Major Business
        2.10.3 Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions
        2.10.4 Mina Therapeutics Recent Developments and Future Plans
    2.11 NeXstar Pharmaceuticals
        2.11.1 NeXstar Pharmaceuticals Details
        2.11.2 NeXstar Pharmaceuticals Major Business
        2.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
        2.11.4 NeXstar Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Nucleic Acid-based Drugs Revenue and Share by Players (2024 & 2030)
    3.2 Nucleic Acid-based Drugs Players Head Office, Products and Services Provided
    3.3 Nucleic Acid-based Drugs Mergers & Acquisitions
    3.4 Nucleic Acid-based Drugs New Entrants and Expansion Plans

4 Global Nucleic Acid-based Drugs Forecast by Region
    4.1 Global Nucleic Acid-based Drugs Market Size by Region: 2024 VS 2030
    4.2 Global Nucleic Acid-based Drugs Market Size by Region, (2024-2030)
    4.3 North America
        4.3.1 Key Companies of Nucleic Acid-based Drugs in North America
        4.3.2 Current Situation and Forecast of Nucleic Acid-based Drugs in North America
        4.3.3 North America Nucleic Acid-based Drugs Market Size and Prospect (2024-2030)
    4.4 Europe
        4.4.1 Key Companies of Nucleic Acid-based Drugs in Europe
        4.4.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Europe
        4.4.3 Europe Nucleic Acid-based Drugs Market Size and Prospect (2024-2030)
    4.5 Asia-Pacific
        4.5.1 Key Companies of Nucleic Acid-based Drugs in Asia-Pacific
        4.5.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Asia-Pacific
        4.5.3 Asia-Pacific Nucleic Acid-based Drugs Market Size and Prospect (2024-2030)
        4.5.4 China
        4.5.5 Japan
        4.5.6 South Korea
    4.6 South America
        4.6.1 Key Companies of Nucleic Acid-based Drugs in South America
        4.6.2 Current Situation and Forecast of Nucleic Acid-based Drugs in South America
        4.6.3 South America Nucleic Acid-based Drugs Market Size and Prospect (2024-2030)
    4.7 Middle East & Africa
        4.7.1 Key Companies of Nucleic Acid-based Drugs in Middle East & Africa
        4.7.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Middle East & Africa
        4.7.3 Middle East & Africa Nucleic Acid-based Drugs Market Size and Prospect (2024-2030)

5 Market Size Segment by Type
    5.1 Global Nucleic Acid-based Drugs Market Forecast by Type (2024-2030)
    5.2 Global Nucleic Acid-based Drugs Market Share Forecast by Type (2024-2030)

6 Market Size Segment by Application
    6.1 Global Nucleic Acid-based Drugs Market Forecast by Application (2024-2030)
    6.2 Global Nucleic Acid-based Drugs Market Share Forecast by Application (2024-2030)

7 Research Findings and Conclusion

8 Appendix
    8.1 Methodology
    8.2 Research Process and Data Source
    8.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Nucleic Acid-based Drugs Revenue by Type, (USD Million), 2024 VS 2030
    Table 2. Global Nucleic Acid-based Drugs Revenue by Application, (USD Million), 2024 VS 2030
    Table 3. Ionis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 4. Ionis Pharmaceuticals Major Business
    Table 5. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
    Table 6. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 7. Sarepta Therapeutics Major Business
    Table 8. Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions
    Table 9. Nippon Shinyaku Corporate Information, Head Office, and Major Competitors
    Table 10. Nippon Shinyaku Major Business
    Table 11. Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions
    Table 12. BioNTech Corporate Information, Head Office, and Major Competitors
    Table 13. BioNTech Major Business
    Table 14. BioNTech Nucleic Acid-based Drugs Product and Solutions
    Table 15. Moderna Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 16. Moderna Therapeutics Major Business
    Table 17. Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions
    Table 18. CureVac Corporate Information, Head Office, and Major Competitors
    Table 19. CureVac Major Business
    Table 20. CureVac Nucleic Acid-based Drugs Product and Solutions
    Table 21. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 22. Alnylam Pharmaceuticals Major Business
    Table 23. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
    Table 24. Regulus Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 25. Regulus Therapeutics Major Business
    Table 26. Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions
    Table 27. Miragen Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 28. Miragen Therapeutics Major Business
    Table 29. Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions
    Table 30. Mina Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 31. Mina Therapeutics Major Business
    Table 32. Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions
    Table 33. NeXstar Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 34. NeXstar Pharmaceuticals Major Business
    Table 35. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
    Table 36. Global Nucleic Acid-based Drugs Revenue (USD Million) by Players (2024 & 2030)
    Table 37. Global Nucleic Acid-based Drugs Revenue Share by Players (2024 & 2030)
    Table 38. Nucleic Acid-based Drugs Players Head Office, Products and Services Provided
    Table 39. Nucleic Acid-based Drugs Mergers & Acquisitions in the Past Five Years
    Table 40. Nucleic Acid-based Drugs New Entrants and Expansion Plans
    Table 41. Global Market Nucleic Acid-based Drugs Revenue (USD Million) Comparison by Region (2024 VS 2030)
    Table 42. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2024-2030)
    Table 43. Key Companies of Nucleic Acid-based Drugs in North America
    Table 44. Current Situation and Forecast of Nucleic Acid-based Drugs in North America
    Table 45. Key Companies of Nucleic Acid-based Drugs in Europe
    Table 46. Current Situation and Forecast of Nucleic Acid-based Drugs in Europe
    Table 47. Key Companies of Nucleic Acid-based Drugs in Asia-Pacific
    Table 48. Current Situation and Forecast of Nucleic Acid-based Drugs in Asia-Pacific
    Table 49. Key Companies of Nucleic Acid-based Drugs in China
    Table 50. Key Companies of Nucleic Acid-based Drugs in Japan
    Table 51. Key Companies of Nucleic Acid-based Drugs in South Korea
    Table 52. Key Companies of Nucleic Acid-based Drugs in South America
    Table 53. Current Situation and Forecast of Nucleic Acid-based Drugs in South America
    Table 54. Key Companies of Nucleic Acid-based Drugs in Middle East & Africa
    Table 55. Current Situation and Forecast of Nucleic Acid-based Drugs in Middle East & Africa
    Table 56. Global Nucleic Acid-based Drugs Revenue Forecast by Type (2024-2030)
    Table 57. Global Nucleic Acid-based Drugs Revenue Forecast by Application (2024-2030)
List of Figures
    Figure 1. Nucleic Acid-based Drugs Picture
    Figure 2. Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2030
    Figure 3. ASO
    Figure 4. mRNA
    Figure 5. siRNA
    Figure 6. miRNA
    Figure 7. saRNA
    Figure 8. Aptamer
    Figure 9. Nucleic Acid-based Drugs Revenue Market Share by Application in 2030
    Figure 10. Genetic Disease Picture
    Figure 11. Cancer Picture
    Figure 12. Cardiovascular Diseases Picture
    Figure 13. Other Picture
    Figure 14. Global Nucleic Acid-based Drugs Market Size, (USD Million): 2024 VS 2030
    Figure 15. Global Nucleic Acid-based Drugs Revenue and Forecast (2024-2030) & (USD Million)
    Figure 16. Nucleic Acid-based Drugs Market Drivers
    Figure 17. Nucleic Acid-based Drugs Market Restraints
    Figure 18. Nucleic Acid-based Drugs Market Trends
    Figure 19. Ionis Pharmaceuticals Recent Developments and Future Plans
    Figure 20. Sarepta Therapeutics Recent Developments and Future Plans
    Figure 21. Nippon Shinyaku Recent Developments and Future Plans
    Figure 22. BioNTech Recent Developments and Future Plans
    Figure 23. Moderna Therapeutics Recent Developments and Future Plans
    Figure 24. CureVac Recent Developments and Future Plans
    Figure 25. Alnylam Pharmaceuticals Recent Developments and Future Plans
    Figure 26. Regulus Therapeutics Recent Developments and Future Plans
    Figure 27. Miragen Therapeutics Recent Developments and Future Plans
    Figure 28. Mina Therapeutics Recent Developments and Future Plans
    Figure 29. NeXstar Pharmaceuticals Recent Developments and Future Plans
    Figure 30. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2024-2030)
    Figure 31. Global Nucleic Acid-based Drugs Revenue Market Share by Region in 2030
    Figure 32. North America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 33. Europe Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 34. Asia-Pacific Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 35. South America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 36. Middle East & Africa Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 37. Global Nucleic Acid-based Drugs Market Share Forecast by Type (2024-2030)
    Figure 38. Global Nucleic Acid-based Drugs Market Share Forecast by Application (2024-2030)
    Figure 39. Methodology
    Figure 40. Research Process and Data Source

Companies Mentioned

Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals